Umanath Kausik, Niecestro Robert, Lewis Julia B, Dwyer Jamie P
a Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA.
b Independent Consultant, Pocono Pines, PA, USA.
Expert Rev Endocrinol Metab. 2013 Jan;8(1):13-19. doi: 10.1586/eem.12.66.
Ferric citrate (KRX-0502; Keryx Biopharmaceuticals, Inc., NY, USA) is a novel phosphate-binding agent presently in Phase III clinical development. Ferric citrate dissociates in the bowel lumen releasing the ferric ion to precipitate with dietary phosphorus, which is then excreted in the stool. Studies to date have shown the agent to be efficacious and safe with only mild gastrointestinal side effects. Absorption of either component of the agent (ferric iron or citrate) has the potential to be of benefit for patients with end-stage renal disease. An ongoing Phase III trial is confirming the safety and efficacy of ferric citrate as a phosphate binder in dialysis patients.
柠檬酸铁（KRX - 0502；美国纽约的凯瑞克斯生物制药公司）是一种新型的磷结合剂，目前正处于III期临床开发阶段。柠檬酸铁在肠腔内解离，释放出铁离子与膳食中的磷结合沉淀，然后随粪便排出。迄今为止的研究表明，该药物有效且安全，仅伴有轻微的胃肠道副作用。该药物的任何一种成分（铁离子或柠檬酸盐）的吸收都有可能对终末期肾病患者有益。一项正在进行的III期试验正在证实柠檬酸铁作为透析患者磷结合剂的安全性和有效性。
